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Summary 
Natural killer (NK) cells are large granular lymphocytes thought to be important in the host's 
early immune response to viral infection and malignant transformation. NK cells proliferate and 
display enhanced cytotoxic activity in response to the T cell growth factor, interleukin 2 (IL-2). 
Stem cell factor or steel factor (SF) is the ligand for the c-kit receptor,  and when combined with 
other hematopoietic growth factors, SF synergistically promotes the proliferation and differentiation 
of bone marrow stem cells. In the present study we show the c-kit receptor to be uniquely expressed 
on a subset of resting human NK cells (CD56b~s  ht) which constitutively expresses both the high 
affinity IL-2 receptor (IL-2R) and the intermediate affinity IL-2R. Other lymphocyte populations, 
including CD56  dim NK cells, did not appear to express the c-kit receptor. Within the CD56bng  ht 
NK cell subset, SF alone had no obvious effect on proliferation or cytotoxic activity.  SF was 
shown to significantly augment the proliferative  effect of IL-2, and caused a marked shift in 
the dose-response curve at IL-2 concentrations that selectively saturate the high affinity IL-2R. 
The potentiating effect of SF on NK cell proliferation was dependent on IL-2 binding to the 
high affinity IL-2R, and was blocked by a monoclonal antibody directed against the c-kit receptor. 
SF did not enhance proliferation at higher IL-2 concentrations that saturate  the intermediate 
affinity IL-2R, nor did SF enhance IL-2-induced cytotoxic activity. Together, these data indicate 
that SF and IL-2 act synergistically  to directly augment the proliferative  capacity of a unique 
human NK cell subset constitutively expressing the high affinity IL-2R and the c-kit receptor. 
The implications of these findings on NK cell development and the host's early immune response 
to pathogen invasion  are discussed. 
N 
'K cells are a distinct population of large granular lym- 
phocytes that appear to have an important role in the 
host's early immune response to viral infection and malig- 
nant transformation. NK cells show a proliferative  and en- 
hanced cytotoxic response to IL-2, a lymphocytotropic hor- 
mone produced by activated T cells that is essential in normal 
immune responses (for a review see reference 1). Indeed, un- 
like the vast majority of other lymphocyte populations found 
in resting human peripheral blood, most NK cells constitu- 
tively express one or two functional isoforms of the human 
IL-2R. 90% of NK cells can be identified by their low den- 
sity expression of the CD56 antigen (CD56 dim) and express 
an intermediate affinity IL-2tL, now known to be composed 
of at least two subunits, IL-2fl and IL-2"y. A minor subset 
of NK cells, identified by its high density expression of the 
CD56 antigen (CD56bnsht), expresses both the intermediate 
affinity IL-2R and the high affinity IL-2R, composed of three 
subunits that are noncovalently linked to form a heterotrimer 
(IL-2RotBT) (2-5). Saturation of the high affinity IL-2R ex- 
pressed on the CD56bng  ht NK population with low concen- 
trations of IL-2 (i.e., 1-100 pM) results in a profound prolifer- 
ative response with only modest enhancement of cytotoxic 
activity. The intermediate affinity IL-2R, when saturated by 
higher concentrations of IL-2 (i.e.,  1-10 nM), significantly 
enhances  cytotoxic  activity  in  both  the  CD56b~ig  ht  and 
CD56  a~m NK cell populations, yet does not result in any en- 
hancement of proliferation (2). Thus, despite both functional 
IL-2R  isoforms  being  constitutively  expressed  on  the 
CD56  bright NK  cells  and  both  isoforms  possessing  the 
subunits important for signal transduction and internaliza- 
tion (5), significant  proliferation only occurs via the heter- 
otrimeric high affinity  IL-2Kotfl% 
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sine kinase receptor that belongs  to a superfamily that  in- 
dudes the receptors for insulin, platelet-derived growth factor, 
epidermal growth factor, and CSF-1 (6). Within the hema- 
topoietic system the c-kit receptor is expressed on normal bone 
marrow cells at various stages of maturation (7). Steel factor 
(SF) or stem cell factor is a ligand for the c-kit receptor (8, 
9), and together, c-kit receptor and SF are considered to play 
a  major  role  in  the  regulation  of human  hematopoiesis. 
Whereas SF alone has only a modest effect on stem cell prolifer- 
ation  (10),  SF  has been observed to exhibit potent  syner- 
gistic activity with virtually all of the known hematopoietic 
growth factors, including erythropoietin (Epo), IL-3, GM- 
CSF, G-CSF, and IL-6, resulting in increased colony forma- 
tion of both primitive and lineage-specific hematopoietic pro- 
genitor cell populations (11, 12). These hematopoietic growth 
factors specifically bind to their respective receptors which 
all belong to the hematopoietin receptor superfamily that also 
includes IL-2RB and IL-2R3' (5,  13).  Because SF has been 
shown to augment the proliferative effects mediated via the 
hematopoietin  receptors constitutively expressed on hema- 
topoietic stem cells, we hypothesized that SF may also poten- 
tiate functional responses of IL-2 in human  NK cells that 
constitutively express IL-2R. In the present study, we dem- 
onstrate that the CD56bng  ht NK cell appears unique among 
resting human lymphocytes in its constitutive expression of 
the c-kit receptor, and have performed a functional character- 
ization of the interactions between SF and IL-2 on this lym- 
phocyte population. 
Materials  and Methods 
raAbs.  Nonreactive mouse immunoglobulin (Mslg) was pur- 
chased from Sigma Immunochemicals (St. Louis, MO). NKH1 (anti- 
CD56)-PE was from Coutter Immunology (Hialeah, FL). Leu16 
(anti-CD20)-PE, and Leu4 (anti-CD3)-PE, were from Becton Dick- 
inson & Co. (San Jose, CA). YB5.B8 is the anti-c-kit receptor mAb 
(14). Clone 3D3.3 is a nonreactive isotype control. Purified anti- 
Tac (anti-CD25) was kindly provided by Dr. Kendall Smith (Cot- 
nell Medical School, New York), and purified mAb 2T8-SH7 was 
used as a nonreactive isotype control. Anti-CD4 and anti-CD5 were 
kindly provided by Dr. Stuart Schlossman  (Dana Farber Cancer 
Institute, Boston, MA). 3F5B11 is a IgG1 murine mAb developed 
in our laboratory and is reactive with monomorphic HLA-DR. 
FITC-conjugated goat anti-mouse IgG was from Tago, Inc. (Burlin- 
game, CA). 
Immunofluorescence Analysis of  Lymphocyte Subsets  for c-kit Receptor 
Express/on.  PBL were analyzed for simultaneous two-color immuno- 
fluorescent expression of the c-kit receptor and either CD56  b~ight 
and CD56 ~m (NK cells), CD20 (B cells), or CD3 (T cells). Fresh 
peripheral blood was obtained from healthy donors for isolation 
of PBMC with Ficoll-Hypaque separation,  and adhered for 1 h 
at 37~  106 nonadherent PBMC were then incubated on ice with 
either anti-c-kit receptor mAb or with a nonreactive isotype con- 
trol mAb, washed once, incubated with goat anti-mouse-FITC, 
washed twice, and incubated with directly conjugated mAb CDS6- 
PE, CD20-PE, CD3-PE, or a nonreactive MsIg-PE control mAb. 
Background fluorescence was determined on cells stained with the 
nonreactive IgG1 isotype control plus indirect FITC and the directly 
conjugated nonreactive PE-control. A  total of 10,000 cells were 
then analyzed in  each  sample  using  the lymphocyte gait  on  a 
FACScan  |  and results were displayed as an orthographic projec- 
tion plotting log green vs log red fluorescence  using the Lysis 
II  |  software program (Becton Dickinson & Co.). CD56bng  h~ and 
CD56 dim cells were separated  based  on fluorescence  intensity of 
CD56 (2). Because the initial analysis of 10,000 PBL collected <200 
CD56  b~gh~ cells, the FL2 amplifier gain of the FACScan  |  was ad- 
justed to trigger selectively on the CD56  b~gh~ cells while analyzing 
~10  ~ nonadherent PBL which were simultaneously stained  with 
anti-CD56-PE and either control mAb-FITC or anti-c-kit receptor- 
FITC. 3,000 CD56 b~gh~ cells were collected and analyzed  on six 
different individuals. 
CD56 ~ght NK Cell Isolation.  Fresh nonadherent PBMC were 
depleted of T  cells, monocytes, B cells, and HLA-DR + progen- 
itor cells by incubating PBL in anti-CD4 (1:1000), anti-CD5 (1:400), 
and anti-HLA-DR (1:100) sterile murine ascites, washing twice, 
and then incubating with goat anti-mouse mAb coupled to im- 
munomagnetic beads (Advanced Magnetics, Inc., Cambridge, MA). 
Cells  were next adhered to a MaxSep Magnetic Cell Separator 
(Baxter HealthCare Corp., Deerfield, IL) for 10 min. Nonadherent 
cells were then labeled with directly conjugated mAbs and sorted 
for  CD56 bright,  CD56 dim,  CD56  bright  c-kit  receptor-positive 
(CD56  b~isht c-kit+),  or CD56  b~ght c-kit- cells on a FACStar Plus* 
cell sorter (Becton Dickinson & Co.). 
Proliferation Assays.  Sorted CD56  b~ight and CD56 aim NK cells 
were plated in U-bottomed wells at a concentration of 2.0  x  104 
cells/well in  KPMI  1640 with  10%  human  AB  serum  (Gibco 
Laboratories,  Grand  Island,  NY)  in  the absence  or presence  of 
varying concentrations of recombinant human Ib2 (sp act 1.5  x 
107 U/ml;  Hoffmann-La Roche, Inc.,  Nutley,  NJ) and varying 
concentrations of recombinant SF ('~36,000 Mr; >103 U/mg pro- 
tein; Immunex, Seattle,  WA). Cells were incubated at 37~  for 
72 or 96 h  as indicated. Proliferation was  measured by methyl- 
[3H]thymidine incorporation during the last  12 h of incubation. 
For high affinity IL-2R blocking experiments,  anti-Tac (anti-CD25) 
mAb was used as affinity-purified  sterile ascites and was added 15 
rain before the addition of Ig2 (2).  For c-kit receptor blocking 
studies,  anti-c-kit  receptor mAb (14) was used as affinity-purified 
sterile ascites and was added 15 min before the addition of SF. Iso- 
type control mAbs, affinity purified in an identical fashion to ex- 
perimental reagents, were used in blocking studies.  Cell number 
and viability were determined by trypan blue dye exclusion.  Cells 
incubated in "medium only" were in RPMI  1640 supplemented 
with  10%  human AB serum. 
Cytotoxicity Assays.  Chromium release assays were performed 
in  triplicate  as  described  (2).  Sorted populations  of CD56  b~ght 
c-kit + and CD56  bagh~ c-kit- cells were plated in medium alone and 
mixed immediately with 4  x  103 SlCr-labeled K562 target cells 
(E/T 10:1), or incubated for 18 h at 37~  in the presence of 10 nM 
IL-2 (,~2,300 U/m1) and then mixed with 4  x  103 SlCr-labeled 
COLO 205  target cells (E/T 10:1). 
ELISA for SE  A sandwich-type ELISA to determine the con- 
centration of SF in RPMI 1640 medium containing 10% human 
AB serum was kindly performed by L. G. Bennett at Amgen, Inc. 
(Thousand Oaks, CA) (15). 
StatisticalAnalysis.  Results of experimental points obtained from 
multiple experiments were reported as the mean _+ 1 SE. Significance 
levels were determined by two-sided student's t test analysis. 
Results 
Selective  Expression  of the c-kit Receptor on  the  CD56 ~ght 
Subset of Human  NK  Cells in Resting Human  PBL.  Fresh 
1080  c-kit Receptor Expression on Human Natural Killer Cells PBL were analyzed for the expression of the c-kit receptor 
in combination with a series of mAbs specific for various lym- 
phocyte populations. Surprisingly,  the only lymphocyte popu- 
lation  to consistently show constitutive expression of the 
c-kit receptor was the CD56b'ig ht subset of NK cells, which 
represents <2%  of PBL.  CD56 dim NK cells  and CD56"eg 
lymphocytes failed to demonstrate any reactivity with the 
anti-c-kit receptor mAb which was above background staining 
(Fig.  1). In an analysis of six different individuals, 45.1  _+ 
8.6% of CD56b~  ht cells coexpressed c-kit receptor (CD56 hight 
c-kit+).  Other lymphocyte populations,  including CD3+  T 
and CD20 + B cells failed to show any significant expression 
of the c-k/t receptor by flow cytometric analysis. Incubation of 
NK cells in 1 nM IL-2 did not result in an upregulation of 
c-kit receptor expression on CD56h~  "ht or CD56  ~  NK cells, 
and incubation in SF did not appear to upregulate CD25 (IL- 
2Ro  0  or IL-2RB expression  (data not shown). 
The CD56~ ~t c-kit + Cell Demonstrates  both NK  and LAK 
Activity.  NK cells are best defined functionally by their ability 
to lyse target cells without deliberate prior sensitization  and 
without restriction by MHC antigens (NK activity).  In addi- 
tion, NK cells demonstrate cytotoxic activity against NK-resistant 
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Figure  1.  Flow cytometric analysis of unsorted PBL from a representa- 
tive normal donor showing the selective expression of c-kit receptor on 
the CD56b~  ht subset of human NK cells. (A and B) Analysis of 10,000 
PBL, indicating the relative percentage of CD56b'is  ht cells. Arrow (B) in- 
dicates CD56b"g  ht cells in PBL coexpressing c-kit receptor (i.e., '~0.77%), 
whereas the isotype control (A, quadrant  2) indicates only 0.06% reac- 
tivity. In contrast,  for the CD56- and CD56  alto cells, there is no differ- 
ence between the isotype control binding (3.89%,  A,  quadrant 3), and 
the c-kit receptor binding (3.47%,  B, quadrant 3). (C and D) The FL-2 
(PE) amplifier gain of the FACScan  |  is adjusted to trigger selectively on 
the CD56bris  ht cells while analyzing "~llP  unsorted PBL which were 
simultaneously stained with anti-CD56-PE and either isotype control mAb- 
FITC (C, quadrant 2) or anti-c-kit receptor-FITC (D, quadrant 2). 3,000 
CD561'~  ht cells were collected. (D) 56.1% of these cells coexpress the c-kit 
receptor; (C) only 3.37% react with the isotype control mAb, giving a 
net CD56b~g  ht c-kit+  of 53%. 
target cells after exposure to IL-2 (LAK activity) (1). To show 
that  CD56  b~t  c-kit + cells possessed NK activity and were 
responsive to IL-2, CD56bri~  t c-kit + and CD56brig  ht c-kit-  cells 
were sorted by FACS  |  and plated immediately in a cytotoxicity 
assay against the NK-sensitive K562 cell line, or incubated over- 
night in 10 nM IL-2 and then plated in a cytotoxicity assay 
against the NK-resistant COLO 205 cell line The results, shown 
in  Fig.  2,  demonstrate that  CD56b~  ht c-kit + cell  possesses 
significant  NK  and  LAK  activity,  although  less than  the 
CD56b~ t c-kit-  fraction. 
The effect of SF on NK and LAK activity was also evalu- 
ated.  When resting CD56b'~ ht NK cells were cultured in a 
high ('~7 nM or 250 ng/ml) concentration of SF alone, cyto- 
toxicity against K562 tumor cell targets was not significantly 
increased over that seen in medium alone  Furthermore, the 
addition of "~7 nM SF to cultures containing low (10 pM or 
•2.3  U/ml) or high (1 nM or "o230 U/ml) concentrations 
of IL-2 did not enhance the LAK activity mediated via the high 
or intermediate affinity IL-2R, respectively (data not shown). 
Effects of SF on IL-2-induced NK  Cell Proliferation.  Highly 
purified CD56b~ t NK cells isolated from resting human pe- 
ripheral  blood failed to demonstrate any significant enhance- 
ment of proliferation when incubated in the presence of medium 
plus SF. It has been shown previously that 10 pM of IL-2 selec- 
tively saturates the high affinity IL-2P, constitutively expressed 
on the CD56  h~ht subset of NK cells and induces a significant 
proliferative response (2, 3), as evidenced by the 10-fold increase 
in [3H]thymidine incorporation over baseline seen in Fig. 3 A. 
The simultaneous  addition of '~7  rum SF  and 10 pM  IL-2 
resulted in a proliferative response that was over threefold higher 
than that seen with IL-2 alone (p <0.01), and 30-fold higher 
than baseline levels of proliferation  with medium or SF alone 
(Fig. 3 A). Consistent with this, the number of cells in wells 
containing SF and IL-2 was 65% greater than the number of 
cells in wells containing IL-2 alone, when enumerated at 96 h. 
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Figure  2.  Functional characterization  of the CD56b~B  ht  c-kit +  cell. 
CD56brig  ht c-kit-  ([]) and CD56brlg  ht c-kit + (m) cells were sorted from 
fresh PBL and either placed immediately into a 4-h cytotoxicity assay  with 
slCr-labeled K562 target cells (NK activity), or cultured overnight in the 
presence of 10 nM IL-2 and then placed into a 4-h cytotoxicity assay with 
the SlCr-labded COLO 205 target  cells (LAK activity). E/T ratio was 
10:1. Resuhs  are the mean  +  SE for triplicate wells. 
1081  Matos et al.  Brief Definitive Report A 
e- 
o 
o  A 
o  o 
rJ  1,- 
-=  x 
n-  :f 
'D  O.. 
I--  O 
e~ 
B 
Media  SF  iL2  IL2  +  IL2  * 
0.7  nM  SF  7.0  hid  SF 
Culture  Conditions 
e- 
O  m 
o 
m 
o. 
100 
II0 
g0 
40 
30 
IL2  ÷ 
cnU  mAb 
IL2  ÷  8F 
+  cntl  mAb 
Culture 
IL2  + 
antI-T~,c 
Conditions 
IL:D  +  8F 
+  anti-Tee 
A 
g 
;A 
_tie 
D. 
I--  5' 
Figure  3. 
15 ¸ 
........  ;  ........  i  ........  ,  ........  i 
0.1  1  10  100  1000 
IL-2  Concentration  (pM) 
The effect of SF on I1,2-induced  proliferation of CD56brig  ht 
NK cells. (A) The effect of SF on Ib2-induced proliferation is synergistic 
and dose dependent.  CD56b~s  ht NK cells were purified from fresh PBL, 
and cultured for 72 h in the presence of medium, ~7 nM SF (250 ng/ml), 
10 pM 11,2 (2.3 U/ml), 10 pM I1,2 and '~0.7 nM SF, or 10 pM I1,2 and 
,v7.0 nM SF. The results  are expressed as the mean CPM  ±  SE from 
triplicate wells. (B) The presence of SF shifts the dose-response  curve of 
11,2-induced  CD56b~s ht proliferation  at limited concentrations  of I1,2. 
Purified CD56b"g  ht NK cells were cultured  at varying concentrations  of 
IL-2 for 72 h in the presence (e) or absence (O) of,v7 nM SF. This figure 
is representative of three independent  experiments. 
At 10 pM IL-2, the enhancing effect of SF on proliferation 
of the CD56b~ig  ht population was shown to be dose depen- 
dent, with significant increases in IL-2-induced proliferation 
consistently being seen at SF concentrations between 70 and 
100 pM (data not shown), and a two- to threefold increase 
in proliferation at SF concentrations  between 0.7 and 7 nM 
(Fig. 3 A). A peak effect was reached at values between 20 
and 27 nM (data not shown). The effect of SF was also shown 
to be time dependent. Cells cultured for 96 h after the simul- 
taneous addition of SF and IL-2 demonstrated a proliferative 
response that was 40%  greater than cells cultured  in IL-2 
for 24 h before the addition  of SF and for cells cultured in 
SF  for  24  h  before  the  addition  of  IL-2.  In  addition, 
CD56b~ig  ht NK cells cultured simultaneously in SF and IL-2 
proliferated in vitro for up to 6 d beyond that seen with IL-2 
alone  (data not shown). 
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Figure  4.  (.4)  The potentiating  effect of SF on CD56brig  ht NK cell 
proliferation  requires I1,2 binding to the high affinity I1,2R. CD56brig  ht 
NK cells from fresh PBL were cultured for 72 h in 10 pM IL-2, or ~7 
nM SF plus 10 pM I1,2. Before the addition of I1,2, calls were incubated 
with either a nonreactive mAb or anti-Tac  (anti-CD25) mAb. (B) The poten- 
tiating  effect of SF on CD56brlg  ht NK cell proliferation  is abrogated by 
a mAb to the c-kit receptor. CD56b~s  ht NK cells were cultured for 72 h 
in 10 pM I1,2 or 10 pM Ib2 plus rv140 pM SF. Before the addition of 
SF, cells were incubated with either a nonreactive mAb or anti-c-kit mAb. 
Results  are expressed as percentage of maximum pH]TdK incorporation 
_+ SE for three to four replicate wells. 
The addition of SF to CD56brig  ht NK ceils cultured at in- 
creasing concentrations  of IL-2 resulted in a distinct  shift of 
the IL-2 proliferative dose-response curve (Fig. 3 B). In the 
absence of SF, CD56brig  ht NK cells required 25 pM IL-2 to 
achieve 50% of the maximal proliferative response, whereas 
in the presence of ,'~7 nM SF, CD56b"s  ht NK cells achieved 
a comparable response with only 3 pM IL-2.  Importantly, 
SF induced this synergistic proliferative response only at those 
concentrations  of IL-2 that saturate the high affinity IL-2R 
(i.e.,  1-100 pM) (16).  CD56  bright cells cultured  in the pres- 
ence of SF and higher concentrations  of IL-2 (i.e., 1-10 pM), 
which saturate both the high and the intermediate  affinity 
IL-2R expressed on these cells, did not show further increases 
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IL-2.  CD56 dim  NK  cells, which  only express  the  inter- 
mediate affinity IL-2R and do not appear to express the c-kit 
receptor,  did not show any significant proliferation  in the 
presence of SF and 1 nM IL-2 (data not shown). 
Requirement of High Affinity IL-2R Binding.  To investigate 
whether IL-2 binding to the high affinity IL-2R was required 
for the potentiating effect of SF on CD56bng  h~ proliferation, 
cells were cultured in the presence or absence  of anti-Tac (anti- 
CD25) mAb. The addition of anti-Tac mAb to CD56b~ig  h~ 
cells cultured in 10 pM IL-2 abrogates the proliferative re- 
sponse by inhibiting the binding of IL-2 to the high affinity 
IL-2R (2,  16). As can be seen in Fig. 4 A, CD56b~ig  ht NK 
cells incubated in the presence of anti-Tac mAb and 10 pM 
IL-2 achieved  only 10.2% of the proliferative  response achieved 
by cells incubated with control mAb and 10 pM IL-2. Like- 
wise, CD56b~ig  h~ NK cells incubated in the presence of anti- 
Tac mAb, 10 pM IL-2 and '~7 nM SF achieved only 19.6% 
of the proliferative response of cells incubated in control mAb, 
IL-2,  and SF. This proportional reduction in the presence 
of anti-Tac mAb indicates that the potentiating effect of SF 
on CD56b~g  ht NK cell proliferation  is dependent on IL-2 
binding to the high affinity IL-2R. 
Functional  Characterization  oft-kit Receptor Expression  on the 
CD56~g ht NK Cells.  The anti-c-kit receptor mAb YB5.B8 
inhibits  the binding of SF to the c-kit receptor (14). Addi- 
tional functional studies were performed on the CD56bng  h~ 
NK cells in the presence of anti-c-kit receptor mAb to deter- 
mine if effects of SF were mediated via the constitutively ex- 
pressed c-kit receptor. CD56bng  h~ cells purified from resting 
PBL were incubated in the presence of either the isotype con- 
trol mAb or anti-c-kit  receptor mAb before the addition of 
10 pM IL-2 and "~140 pM (5.0 ng/ml) of SF. As can be seen 
from Fig. 4 B, the presence of the anti-c-kit  receptor mAb 
abrogated the enhancing effect of SF on IL-2-induced prolifer- 
ation in the CD56b~s  ht NK subset (p ~<0.006). SF therefore 
appears to mediate its effect via the c-kit  receptor. Impor- 
tantly, Fig. 4 B also shows that cells incubated in 10 pM IL-2 
and concentrations of SF which approximate those found in 
vivo (3.3. ng/ml or ",~90 pM) (15), demonstrate a prolifera- 
tive response that is significantly greater than that seen with 
cells incubated in 10 pM IL-2 and 10%  human AB serum 
(0.3 ng/ml of SF) (p ~<0.03). 
Discussion 
In the present study, we report that the CD56brig  ht subset 
of human NK cells constitutively expresses  functional receptors 
encoded  by the c-kit protooncogene. Whereas the expression 
of the c-kit receptor has previously been found on a broad 
range of hematopoietic and nonhematopoietic  cell types (14), 
expression on resting human lymphocytes  has not previously 
been reported. By flow cytometric analyses, c-kit receptor ex- 
pression  on  lymphocytes appears to  be  restricted  to  the 
CD56bns  ht NK subset. The studies demonstrating significant 
NK and LAK activity within the CD56bas  ht c-kit + fraction 
provide evidence that this population fulfills the functional 
definition of NK cells. The CD56bag  ht NK subset represents 
~<2% of human PBL, and also appears to be unique in its 
constitutive expression  of the high affinity IL-2R (2, 3). Given 
the synergy of SF with other ligands of the hematopoietin 
receptor superfamily (11, 12), we investigated whether the 
SF-c-kit receptor interaction would enhance the functional 
responses  of the CD56b~ig  ht  NK  subset  mediated via  the 
IL-2R. 
The results presented here demonstrate that SF significantly 
enhances  the  IL-2-induced proliferative  response  of the 
CD56b~ig  ht  NK  subset,  and  does  so  in  a  dose-dependent 
fashion. Whereas SF alone has no effect on proliferation,  it 
causes a pronounced shift in the IL-2 dose-response  curve 
at concentrations of IL-2 that selectively saturate the high 
affinity IL-2R (i.e., 1-100 pM). CD56brig  ht NK cells cultured 
in the presence of "~7 nM SF required approximately eight- 
fold less IL-2 to achieve 50% of their maximal proliferative 
response. In addition,  the inhibition of IL-2 binding to the 
high affinity IL-2R with anti-Tac mAb, which results in a 
profound reduction in IL-2-induced proliferation,  propor- 
tionally reduced the proliferation achieved with SF and IL-2. 
Together, these data strongly suggest that signal transduc- 
tion via the IL-2-high affinity IL-2K interaction is a prereq- 
uisite for the enhanced proliferative effect mediated by SF. 
The fact that SF did not augment a proliferative response 
mediated via the intermediate affinity IL-2K at high concen- 
trations of IL-2 is not surprising, since  the intermediate affinity 
IL-2K expressed on  CD56brig  ht or  CD56 dim NK cells does 
not transduce a significant proliferative signal when fully satu- 
rated by IL-2 (2). However, SF did not augment the NK cyto- 
lyric response which is enhanced on all NK cells after activa- 
tion of the intermediate affinity IL-2R by IL-2 (2). SF may 
therefore potentiate an intracellular signal that is specific for 
IL-2-induced proliferation and not IL-2-enhanced cytotoxicity. 
The expression of the c-kit receptor is most abundant on 
the early hematopoietic progenitor populations  and declines 
with terminal myeloid and erythroid differentiation (7). Na- 
gler et al. (17) performed a phenotypic and functional anal- 
ysis of CD56brig  ht (CD16-) and CD56  dim (CD16 +) human 
NK cells, and proposed that the CD56  basht NK subset is less 
differentiated than the CD56  aim subset. The unique expres- 
sion of the c-kit receptor on the CD56 bright NK subset would 
lend further support  to this proposal,  and may help to ex- 
plain why the CD56hi8  ht c-kit + fraction displays  less NK and 
LAK  activity  than  the  CD56  bright c-kit-  fraction.  The 
proliferation studies performed in the presence of the anti-c- 
kit receptor mAb provide strong evidence  that the potentiating 
effect of SF on CD56bag  ht NK ceils is indeed mediated via 
the  c-kit  receptor.  In  vitro  concentrations of SF  which 
approximate  those found in vivo (15) were found to signi- 
ficantly augment the IL-2-induced proliferative response of 
CD56 bright NK cells when compared with that seen with 
IL-2 alone. SF may therefore have physiologic relevance for 
the CD56b~is  ht NK functional response in vivo when, during 
viral infection, soluble IL-2 is produced by activated T cells. 
Recent work by Miller  et al.  (18) suggests  that IL-2 and 
stromal cell factors such as SF are required for NK cell devel- 
opment from CD34+DR -  progenitor populations in vitro. 
The constitutive expression of the c-kit receptor on this NK 
1083  Matos  et al.  Brief  Definitive Report subset may therefore also serve to promote intimate contact 
with marrow stromal cells expressing the active transmem- 
brahe form of SF during its maturation in vivo. 
In a recent clinical  trial, we have demonstrated that the 
CD56bng  h~  subset  of human  NK cells  can undergo a pro- 
found selective expansion in vivo during a prolonged con- 
tinuous infusion of low dose IL-2. Serum concentrations of 
IL-2 during these infusions ranged between 10 and 200 pM, 
optimal for saturation of the high affinity IL-2R (19). The 
results of our in vitro study reported here suggest that the 
presence of SF in normal human serum may be an important 
component of this selective immune modulation in vivo, and 
that the concomitant administration of exogenous SF might 
produce a more rapid expansion of this NK cell subset at 
a significantly lower concentration of IL-2. Further elucida- 
tion of the mechanisms involved in this potentiating effect, 
as well as other functional consequences of SF on human NK 
cells, should lend additional insights into the role(s) of this 
growth factor in NK cell development and the host's normal 
immune response, and may provide important information 
for the successful  design of future clinical  trials. 
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